Nah..we have covered it over a few iterations in the past...
V high level summary:
- Expensive
- Hit and miss, can work wonders on a few, others are meh.
- Individualised, hard to scale
- None really approved by authorities, maybe a couple but very specific applications
Might develop over time, our market is huge, there would be room for multiple players if Stem Cell area does improve and becomes cheaper/accessible/efficacious
There is prob more scope in eventual combination therapy...ie iPPS and stem cell together.
My thoughts, DYOR
research reports and media, page-4121
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $82.20M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 24.0¢ | 23.0¢ | $133.5K | 564.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 108916 | 23.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 58538 | 2 |
View Market Depth
| Last trade - 16.10pm 17/06/2024 (20 minute delay) ? |
|
|||||
|
Last
23.5¢ |
Change
0.000 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 24.0¢ | 24.0¢ | 23.5¢ | 80791 | ||
| Last updated 15.54pm 17/06/2024 ? | |||||
| PAR (ASX) Chart |
